Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer
Clinical and Molecular Hepatology · 2026
DOI: 10.3350/cmh.2025.1019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, 2026. Verfasst von Daeseong Kim und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Deoxycytidine, Biliary Tract Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Korea Health Industry Development Institute.
Abstract (Originalsprache)
Background/Aims: Biliary tract cancer (BTC) is a rare malignancy with poor prognosis. We investigated genomic determinants of clinical benefit from gemcitabine, cisplatin, and nab-paclitaxel (GAP) versus gemcitabine and cisplatin (GC) in advanced BTC.
Methods
Clinical and genomic data using TruSight Oncology 500 were analyzed from patients treated with GAP (N=198) or GC (N=89) as first-line therapy.
Results
With a median follow-up of 33.0 months, GAP modestly improved progression-free survival (PFS) (hazard ratio [HR] 0.764; 95% confidence interval [CI] 0.591–0.989) without significant overall survival (OS) difference compared to GC. Genomic profiling revealed frequent alterations in TP53 (35.2%), KRAS (16.4%), SMAD4 (10.5%), and TNFRSF14 (10.5%), involving RTK/RAS (44.3%), TP53 (41.8%), and PI3K (20.2%) pathways. Single-gene mutations did not predict treatment benefit. However, pathway-level analysis identified PI3K pathway activation as significantly associated with inferior PFS (HR 2.148; 95% CI 1.478–3.124) and OS (HR 2.096; 95% CI 1.413–3.109) in patients receiving GAP, an effect not observed with GC. Importantly, GAP conferred clinical benefit only in patients without PI3K pathway activation, while no survival advantage was seen in those with such alterations (Pinteraction=0.023 for PFS, Pinteraction=0.003 for OS). Similar results were obtained in the independent validation cohort treated with GAP (N=103) or GC (N=64) for BTC.
Conclusions
Genomic profiling using next-generation sequencing identified PI3K pathway activation as key molecular determinant that differentiates patient outcomes between GAP and GC treatments in advanced BTC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
- Department of Otorhinolaryngology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Department of Life Science, CHA University, Seongnam, Korea.
- Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Division of Gastroenterology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT
- Korea Health Industry Development Institute
- Ministry of Health and Welfare
- Yonsei University College of Medicine
Zitieren
APA
Kim, D., Sim, N. S., Woo, S., Kim, M. H., Lee, C. K., Hong, S. S., Kim, S. H., Hwang, H. K., Kang, C. M., Lee, W. J., Jo, J. H., Chung, T., Hwang, S., Kang, B., Kim, J. S., Kwon, C. I., Kim, S., Chon, H. J., Kim, C. G., …, & Choi, H. J. (2026). Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2025.1019
Vancouver
Kim D, Sim NS, Woo S, Kim MH, Lee CK, Hong SS, et al. Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2025.1019
BibTeX
@article{Kim2026,
author = {Kim, Daeseong and Sim, Nam Suk and Woo, Seonjeong and Kim, Min Hwan and Lee, Choong-Kun and Hong, Seung Soo and Kim, Sung Hyun and Hwang, Ho Kyoung and Kang, Chang Moo and Lee, Woo Jung and Jo, Jung Hyun and Chung, Taek and Hwang, Sohyun and Kang, Beodeul and Kim, Jung Sun and Kwon, Chang-Il and Kim, Sangwoo and Chon, Hong Jae and Kim, Chang Gon and Park, Young Nyun and Choi, Hye Jin},
title = {Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer},
journal = {Clinical and Molecular Hepatology},
year = {2026},
doi = {10.3350/cmh.2025.1019}
}
EUVIMED